A laboratory analysis of GW Pharmaceuticals' cannabis samples of Sativex. Image: PA via   Telegraph.co.uk

GW Pharmaceuticals, which makes drugs derived from the cannabis plant, is scaling up its manufacturing capacity ahead of an expected approval of a new treatment for children with life-threatening epilepsy.

Chief executive Justin Gover said production in 2015 had already increased by 20 times and that this was expected to double further in 2016 to meet "significant" commercial demand for Epidiolex, if it is approved by the US Food and Drug Administration.

Some analysts believe the drug could get the green light in early 2017.

Click here to read the complete article

Julia Bradshaw ~ Telegraph.co.uk ~

Recent News Articles

Monday May 27

Veterans Face Hurdles to Marijuana Access - Cannabis News

in Activism

by Bruce Kennedy - Editor in Chief

The VA does not allow its doctors to prescribe medical marijuana in states where it…

1117 hits

Monday May 27

Legal weed can raise the roof on home prices - Cannabis News

in Real Estate

by Bruce Kennedy - Editor in Chief

Experts suggest that property values get a contact high from retail marijuana because home buyers,…

1584 hits

Monday May 27

How California female cannabis entrepreneurs are overcoming hurdles in fledgling legal industry - Cannabis News

in Finance

by Bruce Kennedy - Editor in Chief

Female business owners face challenges starting and running cannabis operations, according to several such entrepreneurs…

1614 hits

Monday May 27

Has legal cannabis killed the bong? - Cannabis News

in Culture & Arts

by Bruce Kennedy - Editor in Chief

Under cannabis prohibition, nothing signified one’s love of the plant more than bongs – but…

1485 hits

Tuesday May 28

TSA Updates Marijuana Rules To Allow Hemp-Derived CBD On Flights - Cannabis News

in Law & Crime

by Bruce Kennedy - Editor in Chief

The Transportation Security Administration (TSA) updated its policy on cannabis over the Memorial Day weekend,…

1109 hits